Elaine Johnstone
Departmental Lecturer
As a departmental lecturer and Co-Director of the MSc in Experimental and Translational Therapeutics (ETT), my overarching interest is in experimental medicine and patient variability in response. My current responsibilities on the MSc involve curriculum development and pedagogy, academic progress, dissertation development and supervision as well as pastoral support at a graduate and undergraduate level. I am keen to develop my research in education and am interested in outreach and the attainment gap.
I have a BSc in Medicinal Chemistry, an MSc in Molecular Pathology and Toxicology and a PhD in Molecular Pharmacology, which I competed at the Cancer Research Unit, University of Newcastle upon Tyne. After a fellowship studying differential drug response in sarcoma at the University of Bordeaux, I started working at the University of Oxford.
My research at Oxford initially focussed on cancer prevention, studying biological factors influencing effectiveness of smoking cessation therapies (eg NRT). This approach then shifted into cancer patients, identifying genomic factors that influence efficacy and side effects post-treatment. Although I have focussed mainly on biomarkers of treatment outcome, I also have an interest in healthy aging, cancer and exercise, and identifying high risk individuals using biomarkers.
I have a keen interest in education and lots of experience teaching and supporting students to achieve their potential. I recently gained a PGCert in Higher Teaching and Learning with distinction and also a Fellow of the HEA.
Recent publications
-
Synthesis, biological evaluation and mechanism study based on network pharmacology of amino acids esters of 20(S)-protopanaxadiol as novel anticancer agents.
Journal article
Xie H. et al, (2025), Fitoterapia, 180
-
Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial.
Journal article
McGregor MJ. et al, (2015), Anticancer res, 35, 1641 - 1645
-
PTEN loss in the continuum of common cancers, rare syndromes and mouse models.
Journal article
Hollander MC. et al, (2011), Nat rev cancer, 11, 289 - 301
-
What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting?
Journal article
Al-Salama HM. et al, (2009), Discov med, 8, 104 - 107
-
Authors' reply
Journal article
Aveyard P. et al, (2008), Thorax, 63, 291 - 292